EBT-101 for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101
See full descriptionAbout the trial for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Treatment Groups
This trial involves 2 different treatments. EBT-101 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether EBT-101 will improve 1 primary outcome in patients with Human Immunodeficiency Virus Type 1 (HIV-1) Infection. Measurement will happen over the course of 15 years.
Patient Q & A Section
How many people get human immunodeficiency virus type 1 (hiv-1) infection a year in the United States?
Among all people living in a given population, 1 in 35 might be HIV-infected at time of survey. HIV-infected persons represent a risk group that will be included in the growing epidemic. In addition, as with any age-adjusted survey, HIV-infected persons are at higher risk than the general population of developing a HIV-related illness.
What causes human immunodeficiency virus type 1 (hiv-1) infection?
HIV-1 infection causes disease principally as a result of disruption of the host's immune system rather than as a result of direct infection of immune cells.
Can human immunodeficiency virus type 1 (hiv-1) infection be cured?
AIDS has a good prognosis if diagnosis is made soon after exposure to HIV or acquisition of HIV infection during pregnancy. The risk of transmission from an HIV-positive mother to her child, if the child becomes infected during childbirth and/or if the child is infected postnatally are low, the child is generally safer from HIV than the rest of the population. Even people who have passed through multiple STIs or who have tested HIV-infected should assume that their risk for developing AIDS is greater than the rest of the population. Children infected in utero or at birth with HIV-1 disease that is not immediately life-threatening should receive lifelong antiviral treatment to prevent disease progression within the first year of life if they live in industrialized countries.
What are common treatments for human immunodeficiency virus type 1 (hiv-1) infection?
Despite increased use of antiretroviral therapy (ART), there are common ART regimens (tenofovir/emtricitabine/tenafovir; tenofovir/emtricitabine/efavirenz; nevirapine/emtricitabine/tenofovir; efavirenz/emtricitabine/tenofovir; abacavir/lamivudine/zidovudine/tenofovir; lopinavir/ritonavir/emtricitabine/tenofovir), and patients often cite their medications as the things that work better for them.
What are the signs of human immunodeficiency virus type 1 (hiv-1) infection?
To help to develop an effective clinical diagnostic tool for identifying those with HIV/AIDS who are at high risk for transmitting the virus, further research with a larger samples is necessary. In addition, future investigations need to examine viral and immune parameters at different levels, to investigate the possibility of developing new preventive strategies to reduce the further spread of HIV-1.
What is human immunodeficiency virus type 1 (hiv-1) infection?
HIV-1 is a retrovirus that causes AIDS by destroying the body's T-lymphocytes. It can be transmitted in the blood through the semen, vaginal fluids, or breast milk of a person who has AIDS and causes AIDS by destroying the body's T-lymphocytes. HIV-1 has no cure. An alternative mode of transmission of HIV-1 by sexual intercourse with an HIV-1 positive person is still unknown, but recent research suggests that HIV-1 may be a sexual transmitted infection.
How does ebt-101 work?
In a recent study, findings suggest a unique mechanism that ebt-101 induces weight loss with low toxicity and without compromising the ability of hDDC to be produced. While this may be a valuable strategy for treating obesity in other diseases, the use of ebt-101 in hDDC-deficient persons with HIV-1 infection is promising; studies are underway to examine the most efficacious and safest administration route and dosage for those with impaired hDDC production.
Does ebt-101 improve quality of life for those with human immunodeficiency virus type 1 (hiv-1) infection?
Recent findings demonstrate the benefits of oral ebt-101 for HIV patients as it decreased viral load with greater CD4 and CD8 counts, improved QOL, and was well tolerated by the participants. Recent findings also support our work in a Phase I, open-label, open-cycle, phase II, dose-escalating randomized-controlled trial.
What are the latest developments in ebt-101 for therapeutic use?
This drug for therapeutic use is an oral administration form of an active ingredient with an improved bioavailability as compared to the parent drug. This new oral formulation can result in a further reduction in the oral bioavailability of the parent agent.
How serious can human immunodeficiency virus type 1 (hiv-1) infection be?
AIDS has been described as a deadly disease, but this should not be extrapolated from the HIV infections prevalent in an U.S. prison. Although the life expectancy after diagnosis of AIDS is now about 2 years at the current U.S. AIDS case fatality rate of 18%, patients with HIV-1 infection can live for nearly 4 years with full access to medical care and supportive treatment.
What is the latest research for human immunodeficiency virus type 1 (hiv-1) infection?
Although the new therapeutic drugs and strategies for HIV-1 infection are being developed, the latest research is still focused on the biological mechanisms of the pathogenesis of the HIV-1 infection. So there is much to be discovered in the future.
What is the primary cause of human immunodeficiency virus type 1 (hiv-1) infection?
In a recent study, findings are in favor of the hypothesis that HIV-1 infection is the main risk factor for acquiring the virus and the only identifiable etiological factor for chronic infection.